TargetBeta
SSTR2
somatostatin receptor 2 · Somatostatin receptors
6 programs in company-led studies act on SSTR2, from 4 companies: 2 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Octreotiderule | Novartis | phase 4 | 361 running | SSTR1, SSTR3, SSTR4, SSTR5 | ChEMBL |
| actinium AC-225 dotatate | Bristol-Myers Squibb | phase 3 | 33 running | – | a judged reading |
| Paltusotinerule | Vertex Pharmaceuticals | phase 3 | 91 running | CORT | NCIt |
| SSTR2-targeting Non-peptide Drug Conjugate CRN09682rule | Vertex Pharmaceuticals | phase 2 | 11 running | – | NCIt |
| Actinium Ac 225 SSTR2-targeted Agent RYZ401 | Bristol-Myers Squibb | phase 1 | 11 running | – | a judged reading |
| NTQ6179 | Sino Biopharmaceutical | phase 1 | 11 running | – | the company's pipeline |
Conditions their studies are in
- Acromegaly, 3 programs
- Gastro-enteropancreatic neuroendocrine tumor, 2 programs
- Breast Neoplasms, 1 program
- Diarrhea, 1 program
- Malignant Carcinoid Syndrome, 1 program
- Neuroendocrine Tumors, 1 program
- Obesity, 1 program
- Serotonin Syndrome, 1 program
- Thymoma, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 2026actinium AC-225 dotatate · Bristol-Myers Squibb · phase 3 · NCT05477576
- Feb 2027Actinium Ac 225 SSTR2-targeted Agent RYZ401 · Bristol-Myers Squibb · phase 1 · NCT07165132
- Apr 2027NTQ6179 · Sino Biopharmaceutical · phase 1 · NCT07909837
- Aug 2027Paltusotine · Vertex Pharmaceuticals · phase 3 · NCT07087054
- Aug 2027SSTR2-targeting Non-peptide Drug Conjugate CRN09682 · Vertex Pharmaceuticals · phase 2 · NCT07129252
- Jul 31, 2029Octreotide · Novartis · phase 4 · NCT07623824
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.